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AbstrAct
Objective Patients with SLE have an increased risk of 
atherosclerosis (ATH) that is not adequately explained 
by traditional risk factors. We previously described the 
Predictors of Risk for Elevated Flares, Damage Progression, 
and Increased Cardiovascular disease in PaTients with 
SLE (PREDICTS) atherosclerosis-risk panel, which includes 
proinflammatory HDL (piHDL), leptin, soluble tumour 
necrosis factor-like weak inducer of apoptosis (sTWEAK) 
and homocysteine, as well as age and diabetes. A high 
PREDICTS score confers 28-fold increased odds for 
future atherosclerosis in SLE. The aim of this study is to 
determine whether PREDICTS biomarkers are modifiable by 
common lupus therapies.
Methods This prospective observational study included 
SLE subjects started on new lupus treatments. Leptin, 
sTWEAK, homocysteine and antioxidant function of HDL 
were measured at baseline (prior to drug initiation), 6 
weeks and 12 weeks.
Results 16 subjects started mycophenolate (MMF), 18 
azathioprine (AZA) and 25 hydroxychloroquine (HCQ). 
In MMF-treated subjects, HDL function progressively 
improved from 2.23 ± 1.32 at baseline to 1.37±0.81 
at 6 weeks (p=0.02) and 0.93±0.54 at 12 weeks 
(p=0.009). sTWEAK levels also improved in MMF-treated 
subjects from 477.5±447.1 to 290.3±204.6 pg/mL 
after 12 weeks (p=0.04), but leptin and homocysteine 
levels were not significantly changed. In HCQ-treated 
subjects, only HDL function improved from 1.80±1.29 at 
baseline to 1.03±0.74 after 12 weeks (p=0.05). There 
were no changes in the AZA group. MMF treatment 
was still associated with significant improvements in 
HDL function after accounting for potential confounders 
such as total prednisone dose and changes in disease 
activity. Overall, the mean number of high-risk PREDICTS 
biomarkers at week 12 significantly decreased in the 
entire group of patients started on a new lupus therapy 
(2.1±0.9 to 1.8±0.9, p=0.02) and in the MMF-treated 
group (2.4±0.8 vs 1.8±0.9, p=0.003), but not in the 
AZA or HCQ groups. In multivariate analysis, the odds of 
having a high PREDICTS atherosclerosis risk score at 12 
weeks were lower with MMF treatment (OR 0.002, 95% 
CI 0.000 to 0.55, p=0.03).
Conclusions 12 weeks of MMF therapy improves the 
overall PREDICTS atherosclerosis biomarker profile. 
Further studies will determine whether biomarker 
changes reflect decreases in future cardiovascular 
events.
IntROduCtIOn
There is a well-documented increased risk of 
atherosclerosis (ATH) in patients with SLE.1 
Overall, there is a twofold to 10-fold increased 
risk of myocardial infarction in patients with 
SLE compared with the general population, 
with an even more striking 50-fold increased 
risk in younger women.2 Cardiovascular 
events may also result in greater morbidity and 
mortality in patients with SLE, as patients with 
SLE have higher risk of in-hospital mortality 
and prolonged length of hospitalisations 
compared with patients with diabetes and 
patients without SLE and diabetes.3 However, 
although there is an increase in traditional 
Framingham risk factors in patients with 
SLE, these traditional factors alone do not 
fully account for the increased risk of cardi-
ovascular events.4 Thus, other novel inflam-
matory risk factors are likely to contribute to 
the increased ATH seen in SLE. Similar to the 
pathogenesis of other SLE disease manifes-
tations, the formation of the atherosclerotic 
plaque is an inflammatory process, character-
ised by chronic oxidative damage, inflamma-
tory lipid markers and immune cell activation. 
Identification of biomarkers that reflect the 
ongoing inflammation that underlies plaque 
formation will be critical for identifying ther-
apeutic interventions that can halt or prevent 
this process.
Our group has previously identified 
several biomarkers that are associated with 
progression of carotid artery atheroscle-
rosis in patients with SLE. For instance, we 
have shown that proinflammatory high-den-
sity lipoproteins (piHDL) are present more 
frequently in patients with SLE with carotid 
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artery plaque than in those without plaque both in 
cross-section5 and longitudinally.6 Although HDL levels 
are traditionally protective against ATH morbidity and 
mortality, the relationship between HDL and ATH is 
complex and involves both the quantity and function of 
HDL.7 Traditional anti-inflammatory HDL has antioxi-
dant properties; it removes reactive oxygen species (ROS) 
from low-density lipoproteins (LDL), protects LDL from 
oxidation and prevents subsequent recruitment of mono-
cytes to the arterial wall.7 Proinflammatory HDL is unable 
to perform its usual protective role in the prevention of 
ATH. Although studies in the general population and in 
rheumatoid arthritis (RA) have shown that piHDL func-
tion improved with statin therapy (but not to normal 
levels),8 9 the impact of treatments commonly used for 
SLE on HDL function is unknown.
In addition to piHDL, our group has identified several 
other inflammatory biomarkers that are associated with 
plaque and intima-media thickness (IMT) progres-
sion in SLE. We recently discovered that when these 
biomarkers are combined into a panel, PREDICTS, a 
‘high PREDICTS risk’ score confers 28-fold increased 
odds for carotid plaque in SLE women and is also associ-
ated with IMT progression. The biomarkers included are 
piHDL, soluble tumour necrosis factor (TNF)-like weak 
inducer of apoptosis (sTWEAK) (≥373 pg/mL), homo-
cysteine ≥12 μmol/L, leptin ≥34 ng/dL, age ≥48 years 
and type 2 diabetes mellitus.6 Patients with three or more 
risk factors, or diabetes plus one additional risk factor, are 
considered to have ‘high’ PREDICTS risk. It is unknown, 
however, whether these biomarkers are modifiable by 
lupus disease-modifying agents.
We hypothesised that patients with SLE who are treated 
with disease-modifying treatments would have more 
favourable PREDICTS biomarker profiles, particularly in 
regard to piHDL, versus patients with SLE treated with 
other modalities.
PatIents and MethOds
subject selection
In this prospective observational study, we sequentially 
enrolled all patients with SLE in our cohort who were 
started on new lupus-modifying therapies in an 18-month 
period. Patients were excluded if any baseline SLE medi-
cation or statin was started or changed within the 12 weeks 
prior to study entry, or if any changes to background ther-
apies were anticipated during the 12-week study period. 
If subjects had previously taken and discontinued a lupus 
therapy in the past and were restarted on this treatment 
again, they were allowed to enrol in the study as long as 
they had not taken the medication within the previous 
6 months. Subjects were included in the analysis if they 
continued on medication for at least 6 weeks. All eligible 
participants fulfilled ≥4 of the 1997 revised American 
College of Rheumatology (ACR) criteria for classification 
as SLE.10 Although neither study participants nor treating 
physicians were blinded to study medication, biomarker 
assessments were performed in a blinded fashion. All 
participants provided written informed consent.
data collection
Plasma samples were collected and cryopreserved at 
three time points: baseline (prior to initiation of drug), 
6 weeks and 12 weeks postinitiation of therapy. On the 
day of plasma sampling, SLE disease activity was assessed 
using Safety of Estrogens in Lupus Erythematosus 
National Assessment-SLE Disease Activity Index (SELE-
NA-SLEDAI).11 Plasma leptin (BioVendor, Candler, 
North Carolina, USA) and sTWEAK (R&D Systems, 
Minneapolis, Minnesota, USA) were measured using 
ELISA. HDL function was measured as described previ-
ously5 12 using a cell-free assay based on the ability of HDL 
to prevent oxidation. Normal HDL prevents oxidation 
of LDL and dichlorofluorescein diacetate (DCFH-DA), 
which releases a fluorochrome (DCF) on interaction 
with lipid oxidation products. To determine HDL func-
tion, the change in fluorescence intensity from oxidation 
of DCFH/LDL in the presence or absence of test HDL 
was measured. LDL was prepared from normal plasma as 
previously described,12 13 and HDL was prepared from test 
plasma using a dextran sulfate magnetic bead reagent.14 
Twenty-five microlitres of LDL-C (100 μg/mL) was mixed 
with 6.25 μL of test HDL (100 μg HDL-C/mL) in black 
flat-bottom polystyrene microtitre plates and incubated 
at 37°C with rotation for 30 min. Twenty-five microlitres 
of 2.0 mg/mL DCFH solution was then added to each 
well, mixed and incubated at 37°C for 1 hour with rota-
tion. Fluorescence was determined with a plate reader 
(Spectra Max, Gemini XS; Molecular Devices) at an 
excitation wavelength of 485 nm, emission wavelength of 
530 nm and cut-off of 515 nm with photomultiplier sensi-
tivity set at medium. Values of DCF activated by LDL in 
the absence of HDL were normalised to 1.0 fluorescence 
unit as the positive control. Values greater than 1.0 after 
the addition of test HDL indicated dysfunctional, piHDL; 
values less than 1.0 indicated anti-inflammatory (normal) 
HDL. In previously published studies, mean HDL func-
tion in healthy controls ranged from 0.44 to 0.66.8 15
statistical analysis
Data were analysed using STATA V.14.0. Skewed contin-
uous variables were logarithmically transformed to attain 
a normal distribution (note: non-transformed data are 
presented in figures and tables to facilitate interpretation 
of results). For variables that did not attain a normal distri-
bution by logarithmic transformation, non-parametric 
tests were used. Study groups were compared at baseline 
using analysis of variance with Tukey’s analysis of indi-
vidual columns. Changes in individual biomarker meas-
urements over time were compared using paired samples 
t-test and the χ2 test or Fisher’s exact test for categorical 
variables. Either Pearson or Spearman rank correlation 
was calculated, dependent on if the variable was normally 
distributed. The significance level was set at p<0.05.
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Multiple regression analysis was used to build models 
identifying risk factors associated with a change in 
PREDICTS biomarker status at 12 weeks. Generalised 
estimating equations (GEE) were performed to identify 
factors associated with changes in HDL function, sTWEAK 
and leptin over time and to account for the clustering of 
the data within subjects. Different covariance structures 
were examined, including independent, exchangeable, 
autoregressive of order 1 and unstructured matrices. 
Our statistical longitudinal models allowed for interac-
tion terms between time and the treated groups so that 
each treated group could have different progression rates 
over the two time intervals. The quasi-likelihood based 
Akaike’s information criteria QIC and QIC_u criteria for 
generalised estimating equations were used to determine 
the best fitting models.16
Results
Ninety subjects were entered into the study: 20 subjects 
were prescribed mycophenolate mofetil (MMF), 22 
subjects were prescribed azathioprine (AZA) and 27 
subjects were prescribed hydroxychloroquine (HCQ). 
Twenty-one subjects were prescribed other therapies, 
including belimumab (n=5), methotrexate (n=4), cyclo-
phosphamide (n=2), leflunomide (n=2), abatacept 
(n=1), tacrolimus (n=1), rituximab (n=1), and ciclo-
sporin (n=1). Because of the small sample sizes in most of 
the treatment arms, data were only analysed for subjects 
started on MMF, AZA and HCQ. At week 6, 16 subjects 
were still taking MMF, 18 were taking AZA and 24 were 
taking HCQ; these subjects were included in the analysis. 
At the 12-week time point, 15 subjects were still taking 
MMF, 16 were taking AZA and 19 were still taking HCQ. 
Study subjects in all three groups had similar mean 
disease activity at study entry (p=ns), although patients in 
the MMF group were more likely to have active glomeru-
lonephritis than patients in the HCQ group (p=0.05) and 
were also more likely to have a prior history of glomerulo-
nephritis than subjects in either the AZA or HCQ groups 
(table 1).
hdl function is improved in patients with sle taking MMF and 
hCQ, but not aZa
Overall, HDL function improved from baseline to 6 
weeks (p=0.009) and from baseline to 12 weeks (p=0.001) 
in patients with SLE who were started on any new 
disease-modifying therapy (MMF, AZA or HCQ). We 
also examined HDL function changes in each individual 
treatment group. There were no statistically significant 
differences in baseline piHDL levels among the three 
treatment groups. In MMF-treated subjects, HDL func-
tion improved significantly from baseline after 6 weeks 
(p=0.02) and 12 weeks of therapy (p=0.009) (table 2). In 
HCQ-treated subjects, HDL function did not significantly 
change from baseline at 6 weeks of therapy; however, it did 
significantly improve after 12 weeks of therapy (p=0.05). 
In those treated with AZA, HDL function remained rela-
tively stable at 6 and 12 weeks (p=ns).
Improvement in hdl function is not dependent upon 
corticosteroid dose
The mean daily prednisone dose over the 12-week period 
was higher in the MMF-treated and AZA-treated groups 
than in the HCQ group (table 1). In order to account for 
the potential influence of prednisone dosage in the MMF, 
AZA and HCQ treatment groups, we divided each group 
into subjects taking high (≥10 mg/day) and low (<10 mg/
day) daily prednisone doses. There were no significant 
differences in the percentage change of HDL function in 
high versus low prednisone groups in any of the treatment 
arms (data not shown). There were also no significant 
correlations between the mean daily prednisone dose or 
the total prednisone dose taken during the 12-week study 
period and per cent change of HDL function in the total 
cohort (p=ns) or in any individual treatment arm.
Improvement in hdl function is not dependent upon disease 
activity
There was no significant difference in disease activity 
at baseline among the three treatment groups. SELE-
NA-SLEDAI did improve significantly by the 12-week time 
point in all three treatment groups. Although there was 
a strong correlation between per cent improvement in 
SLEDAI score and percent improvement in HDL func-
tion in the MMF group only (r=0.78, p=0.002), there was 
no significant correlation between changes in SLEDAI 
and changes in HDL function in the AZA or HCQ groups 
(figure 1).
Improvement in hdl function in patients taking MMF is 
significant even after accounting for potential confounders
Generalised estimating equations were next used to 
examine the effects of three treatments (MMD, AZA 
and HCQ) on HDL function over three time points and 
adjusting for age, gender, ethnicity, SLEDAI and total 
prednisone use during the study period. After adjusting 
for these variables, patients in the MMF group exhibited 
a significant decrease in HDL function levels over time, 
with the estimated rates of decrease from baseline over 
the 12 weeks −0.71 (p=0.001). The difference in the 
progression rate for the AZA group and the rate in the 
MMF group was 0.63 (p=0.004), suggesting that AZA has 
a progression rate of about −0.08. The corresponding rate 
of decrease in the HCQ group was estimated to be −0.44 
(p=0.31) and not statistically significant. This finding was 
consistent across different types of structures. All covar-
iates, that is, age, gender, SLEDAI and total prednisone 
intake consumption have no significant effects on HDL 
function. This finding was consistent across different 
types of covariance structures. In addition, change in 
HDL function between baseline and at 6 weeks was signif-
icantly different in the MMF and AZA groups (p=0.012) 
and this significance difference persisted between base-
line and at 12 weeks (p=0.005). All other covariates, that 
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Table 2 Changes in PREDICTS biomarkers over 12 weeks according to treatment subgroup
Characteristics Any new IS MMF AZA HCQ
6 week/12 week n=58/50 n=16/15 n=18/16 n=24/19
piHDL baseline 1.88±1.22 2.23±1.32 1.68±1.01 1.80±1.29
piHDL 6 weeks 1.49±1.16 1.37±0.81 1.65±1.15 1.46±1.39
piHDL 12 weeks 1.18±0.91±0.95 0.93±0.54 1.60±1.11 1.03±0.74
P value 0–6 weeks* 0.009 0.02 ns ns
P value 0–12 weeks* 0.001 0.009 ns 0.05
Leptin (ng/dL) baseline 27.9±28.1 36.3±37.7 23.4 ±22.3 25.1±24.2
Leptin 6 weeks 31.3±29.2 45.2±41.1 26.6±23.9 29.9±24.9
Leptin 12 weeks 31.4±28.0 39.0±34.8 25.4±23.2 29.8±26.4
P value 0–6 weeks* ns ns ns ns
P value 0–12 weeks* ns ns ns ns
sTWEAK (pg/mL) baseline 480.1±512.2 477.5±447.1 481.0±630.7 468.1±469.7
sTWEAK 6 weeks 444.1±490.8 387.9±376.8 435.8±496.7 497.2±589.3
sTWEAK 12 weeks 464.6±513.2 290.3±204.6 389.4±475.6 467.8±496.1
P value 0–6 weeks* ns 0.06 ns ns
P value 0–12 weeks* ns 0.04 ns ns
Homocysteine (mmol/L) 10.3±3.6 9.9±3.7 9.1±3.9 10.0±5.6
Homocysteine 12 weeks 9.4±3.3 8.4±3.00 9.7 ±3.9
Homocysteine 12 weeks 9.7±4.6 9.4±3.3 8.4±3.00 9.7 ±3.9
P value 0–12 weeks* ns ns ns ns
SLEDAI baseline 7.4±4.8 8.6 ±7.4 7.7±3.6 6.0±3.1
SLEDAI 6 weeks 5.3±3.6 5.8±4.7 6.17±3.4 4.3±2.6
SLEDAI 12 weeks 4.2±3.3 4.6±4.6 5.4±2.8 2.8±1.9
P value 0–6 weeks* <0.001 0.04 0.07 0.02
P value 0–12 weeks* <0.001 0.01 0.004 <0.001
Bold denotes statistically significant values.
*Paired t-test.
AZA, azathioprine; HCQ, hydroxychloroquine; IS, immunosuppressant; MMF, mycophenolate mofetil; SLEDAI, SLE Disease Activity Index; 
piHDL, proinflammatory high-density lipoprotein; sTWEAK, soluble tumour necrosis factor-like weak inducer of apoptosis.
is, age, gender, SLEDAI and total prednisone consump-
tion had no significant effects on HDL function. Among 
the different ethnic groups, only Asians’ HDL function 
responses differed significantly from that of Caucasians 
on average over time, but when ethnicity was grouped 
more broadly into Caucasians or non-Caucasians, this 
significance disappeared.
stWeaK is improved in patients taking MMF but not aZa or 
hCQ
We next examined whether the other laboratory 
PREDICTS measurements changed in response to 
disease-modifying treatments. Neither leptin nor 
sTWEAK changed with the initiation of any new lupus 
therapy. Levels of sTWEAK did significantly decrease 
after 12 weeks of treatment with MMF (p=0.04) (table 2), 
but this difference was no longer significant in multivar-
iate analysis. sTWEAK did not change in the AZA or HCQ 
treatment arms (table 2). Leptin levels did not signifi-
cantly change over 12 weeks in any of the treatment arms.
the number of PRedICts variables improved in MMF-treated 
patients
We also examined whether treatment with any 
disease-modifying therapy would result in a shift in 
biomarker values from a ‘high risk’ to a ‘lower risk’ 
PREDICTS category. We found that the addition of any 
new lupus therapy resulted in a decrease in the mean 
number of positive PREDICTS variables from 2.1±0.9 to 
1.8±0.9 at 12 weeks (p=0.02). The percentage of patients 
with a high PREDICTS score, however, did not change 
significantly over 12 weeks (32% at baseline vs 33% at 12 
weeks, p=ns). We also examined the impact of individual 
therapies on the overall PREDICTS score. We found that 
overall, the mean number of positive PREDICTS variables 
significantly decreased in the MMF-treated group from 
baseline to 12 weeks (p=0.03). There were no significant 
changes in the AZA or HCQ groups (figure 2).
Logistic regression analysis determined which vari-
ables were associated with a high PREDICTS score at the 
 o
n
 O
ctober 21, 2019 by guest. Protected by copyright.
http://lupus.bmj.com/
Lupus Sci M
ed: first published as 10.1136/lupus-2019-000321 on 27 June 2019. Downloaded from
 
McMahon M, et al. Lupus Science & Medicine 2019;6:e000321. doi:10.1136/lupus-2019-0003216
Lupus Science & Medicine
Figure 1 Correlation between change in SLEDAI and 
change in pro-inflammatory HDL. The percent change 
in SLEDAI correlates with the per cent change in 
proinflammatory HDL from baseline to 12 weeks in (A) 
mycophenolate-treated patients, but not in (B) azathioprine-
treated or (C) hydroxychloroquine-treated subjects. HDL, 
high-density lipoprotein; SLEDAI, SLE Disease Activity Index.
Figure 2 The mean number of PREDICTS risk factors in 
each treatment group at baseline, 6 weeks and 12 weeks. 
PREDICTS scores range from a low of zero to a high 
score of 6. The biomarkers included are soluble tumour 
necrosis factor-like weak inducer of apoptosis (≥373 pg/
mL), proinflammatory high-density lipoprotein, homocysteine 
≥12 μmol/L, leptin ≥34 ng/dL, age ≥48 years and type 2 
diabetes mellitus. The mean PREDICTS score decreased 
significantly from baseline in MMF-treated group over 12 
weeks. AZA, azathioprine; HCQ, hydroxychloroquine; MMF, 
mycophenolate mofetil.
12-week follow-up. The model included baseline number 
of PREDICTS variables, lupus medications, total pred-
nisone intake from 0 to 12 weeks and per cent change 
in SLEDAI over 12 weeks. Independent predictors for a 
high PREDICTS score at 12 weeks included the baseline 
number of PREDICTS variables (OR 20.6, 95% CI 3.3 to 
128.6, p=0.001). Treatment with MMF was inversely asso-
ciated with high PREDICTS at week 12, with an OR of 
0.05 (95% CI 0.003 to 0.93, p=0.05) (see table 3).
dIsCussIOn
In this prospective observational study, we found that 
patients with SLE who initiated treatment with a new 
disease-modifying therapy (MMF, AZA or HCQ) had 
improvements in both inflammatory HDL function and 
the number of high-risk PREDICTS variables. We also 
looked at the impact of different treatments on biomarkers 
of atherosclerosis and found that treatment with MMF 
for 12 weeks decreased two ‘high-risk’ biomarkers of 
atherosclerosis in patients with SLE: inflammatory HDL 
function (in both univariate and multivariate analysis) 
and sTWEAK (univariate analysis only). MMF therapy 
also resulted in a greater likelihood of improvement to 
a lower cardiovascular risk category using the PREDICTS 
model, but treatment with AZA did not. HCQ treatment 
did also result in improvements in HDL function in 
univariate analysis at 12 weeks, but no other significant 
changes to cardiovascular biomarkers were noted. Thus, 
treatment with MMF seems to be associated with better 
improvements in overall cardiovascular risk profile than 
other disease-modifying therapies tested. To our knowl-
edge, this is the first study to demonstrate a change in 
novel biomarkers of atherosclerosis with disease-modi-
fying therapies in patients with SLE.
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Table 3 Logistic regression for the association with a ‘high risk’ PREDICTS score* at 12-week follow-up
Explanatory variable OR 95% CI P value
Initiating MMF therapy 0.002 0.000 to 0.55 0.03
Initiating AZA therapy 0.19 0.01 to 4.1 ns
Total prednisone (mg) 0–12 weeks 1.0 1.000 to 1.001 0.04
% Change in SLEDAI 0–12 weeks 14.6 2.0 to 106.1 0.008
Gender 0.19 0.00 to 5.15E+17 ns
Race/ethnicity 1.3 0.54 to 3.3 ns
Number of PREDICTS variables present at baseline 136.6 4.0 to 4695.7 0.006
*Includes age ≥48 years, piHDL ≥0.94 FU, leptin≥34 ng/mL, sTWEAK ≥373 pg/mL, homocysteine ≥12 mmol/L; high PREDICTS defined as ≥3 
factors or diabetes+1 PREDICTS factor.
AZA, azathioprine; MMF, mycophenolate mofetil; SLEDAI, SLE Disease Activity Index; piHDL, proinflammatory high-density lipoprotein; 
sTWEAK, soluble tumour necrosis factor-like weak inducer of apoptosis.
There is some evidence to support MMF as an athero-
protective medication in SLE. MMF is a prodrug for 
mycophenolic acid (MPA), which inhibits inosine mono-
phosphate dehydrogenase and decreases proliferating 
T and B cells.17 MPA also inhibits both lymphocytic and 
endothelial adhesion molecules, thereby decreasing 
lymphocyte infiltration into the atherosclerotic plaque.17 
MPA also inhibits monocyte and macrophage recruitment 
to plaques.18 Thus, MMF may exert an atheroprotective 
effect in patients by altering the balance of inflammatory 
and protective arterial cell infiltration towards a more 
favourable phenotype. For example, in patients without 
SLE with carotid artery stenosis, 2 weeks of MMF therapy 
resulted in increased numbers of infiltrated regulatory T 
cells and decreased lesion-wide expression of inflamma-
tory genes.19 In a separate study, MMF treatment in an 
ATH-prone SLE mouse model reduced atherosclerosis, 
recruitment of CD4+ T cells to atherosclerotic plaques and 
serum anti-oxidised LDL immunoglobulin G1 compared 
with statin treatment alone.20 In animal models of SLE 
and atherosclerosis, MMF treatment significantly reduced 
atherosclerotic burden in addition to reducing glomeru-
lonephritis.20 21
MMF has several other potential antiatherogenic 
effects that may contribute to its ability to protect from 
ATH progression. MPA decreases oxidative stress and 
reduces formation of ROS by inhibiting interferon 
γ-stimulated and TNFα-stimulated inducible nitric oxide 
synthase (iNOS) activity.22 MMF also decreased other 
markers of oxidative stress in an animal model of cere-
bral ischaemia, including myeloperoxidase (MPO), gluta-
thione, nitric oxide (NO) and malondialdehyde.23 In 
vitro, MMF attenuates MPO activity through inhibition 
of the toll-like receptor 4 (TLR4)/nuclear factor-kappa 
B signalling pathway.24 MMF also inhibits the activity of 
endothelial nicotinamide adenine dinucleotide phos-
phate oxidase oxidase (NOX), which in turn decreases 
endothelial superoxide formation and endothelial 
dysfunction.18 25 Given that MPO, NOX and NOS released 
during the process of NETosis have been implicated in 
the formation of dysfunctional piHDL,26 our findings that 
MMF therapy in patients with SLE improved HDL func-
tion should not be surprising.
There are scant published data regarding the athero-
protective effects of MMF therapy in lupus clinical studies. 
One subgroup analysis from a clinical trial of atorvas-
tatin in patients with SLE did not find any reduction in 
measures of subclinical atherosclerosis in patients taking 
MMF; however, only 25 subjects were included in this anal-
ysis.27 There are some observational data supporting the 
atheroprotective effects of MMF therapy in the non-lupus 
population. In one study of renal transplant recipients, 
longer time on MMF was protective against aortic calci-
fications.28 MMF has also been shown to reduce intimal 
thickness in cardiac transplant patients compared with 
AZA-treated patients.29 Larger prospective randomised 
studies are needed to explore the impact of MMF treat-
ment on cardiovascular disease in SLE.
Although several previous studies have demonstrated 
improvement in traditional lipid profiles with HCQ 
therapy,30–32 this is the first study to our knowledge that 
demonstrates improved HDL function in patients with 
SLE treated with HCQ. HCQ has also been shown to 
have other atheroprotective effects, including improved 
glycaemic control33 and reduced incidence of thrombotic 
events in SLE.34–37 Multiple retrospective cohort studies 
have demonstrated improved overall survival36 38 with 
HCQ use in SLE. HCQ has been associated retrospec-
tively with decreased cardiovascular events in RA,39 and 
non-use of HCQ was associated with increased subclinical 
atherosclerosis in SLE.40 41 Although the exact mecha-
nisms by which antimalarials exert protection are not well 
understood, one study in SLE-prone mice suggested that 
early treatment with HCQ prevents endothelial dysfunc-
tion via an antioxidant effect.42 A randomised controlled 
trial of HCQ versus placebo in preventing cardiovascular 
events in post-myocardial infarction (non-SLE) patients is 
currently underway.43 Larger prospective studies demon-
strating a cardioprotective effect of HCQ in patients with 
SLE are needed.
In our study, therapy with AZA for 12 weeks failed to 
demonstrate any improvement in high-risk cardiovascular 
 o
n
 O
ctober 21, 2019 by guest. Protected by copyright.
http://lupus.bmj.com/
Lupus Sci M
ed: first published as 10.1136/lupus-2019-000321 on 27 June 2019. Downloaded from
 
McMahon M, et al. Lupus Science & Medicine 2019;6:e000321. doi:10.1136/lupus-2019-0003218
Lupus Science & Medicine
biomarkers. This is consistent with other studies in SLE 
that fail to demonstrate any cardioprotective effects with 
AZA. For example, AZA use was associated with increased 
cardiovascular events in the Spanish Registry of Systemic 
Lupus Erythematosus Patients of the Spanish Society of 
Rheumatology registry44 and in the multiethnic LUpus 
in MInoritypopulations: NAture versus Nurture cohort.45 
AZA use was also associated with increased carotid IMT 
in the paediatric SLE Atherosclerosis Prevention in Pedi-
atric Lupus Erythematosus cohort.46 Further studies will 
be needed to determine whether these associations are 
due to a direct effect of AZA or the inability of AZA to 
overcome the inflammation that leads to atherosclerosis.
Similar to our study, several studies have examined 
the impact of disease-modifying antirheumatic drugs 
(DMARDs) therapy on lipid levels and HDL function in 
RA. Although multiple investigations found that DMARD 
therapies in RA are associated with a paradoxical increase 
in hyperlipidaemia, there is some evidence to suggest that 
the increase in lipid levels is associated with improvement 
in HDL function. For instance, the Brigham Rheumatoid 
Arthritis Sequential Study registry study found that in 
patients with RA treated with DMARDs and/or anti-TNF 
agents, improvement in C-reactive protein was associated 
with increased LDL function and improvement in HDL 
function (measured as cholesterol-efflux capacity).47 
Tocilizumab therapy in patients with RA also altered HDL 
composition towards a more anti-inflammatory pheno-
type, despite increases in LDL concentrations.48 The net 
impacts of lipid changes on cardiovascular risk in RA are 
not fully understood, however, and further longitudinal 
studies will be required in both RA and SLE to clarify the 
role of DMARDs in the management of cardiovascular 
risk.
There are several limitations to our study. First, this was 
an observational study, so the subjects were not randomised 
to a treatment group. In addition, background medica-
tion use was not dictated by the study protocol. Patients 
in the MMF and AZA treatment groups did have signifi-
cantly higher prednisone use than those in the HCQ 
group. Even after accounting for cumulative prednisone 
dose during the 12-week period in multivariate analysis, 
however, MMF was still associated with improvements in 
HDL function and with the total PREDICTS score. Sixty-
three per cent and 83% of subjects in the MMF and AZA 
groups, respectively, were also taking background HCQ, 
so it is difficult to determine any additive impact of HCQ 
on cardiovascular biomarkers. However, all subjects had 
been on stable doses of HCQ (and any other non-steroid 
lupus therapies) for at least 12 weeks prior to initiation, 
and no changes to HCQ dose were allowed during the 
investigational period. It is also possible that patients in 
the different medication groups might have had differing 
levels of compliance with therapy, which could decrease 
the effect sizes seen. Finally, although it is encouraging 
that cardiovascular biomarker changes were observed 
during the 12-week duration of this observational study, 
longer studies will be necessary to determine whether 
improvements in cardiovascular risk profiles with MMF 
and HCQ are sustained over time. Further studies will 
also be required to determine if therapeutic lowering of 
cardiovascular risk markers reduces future cardiovascular 
events.
In conclusion, HDL function is significantly improved 
over 12 weeks in patients with SLE treated with MMF or 
HCQ, although not to normal levels. There was no signif-
icant improvement in piHDL function in patients treated 
with AZA over 12 weeks, despite significant improvements 
in SELENA-SLEDAI scores. Using logistic regression, only 
MMF was significantly associated with improvement of 
PREDICTS cardiovascular risk profile. Therefore, MMF 
might offer not only control of glomerulonephritis in 
some patients but might also provide some protection 
from accelerated atherosclerosis in patients with SLE.
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